When does Stelara's main US patent expire?
Stelara's (ustekinumab) primary US patent is set to expire in September 2023 [1][2].
What about Stelara's European patent timeline?
In Europe, the patent protection for Stelara is anticipated to end around July 2024 [2].
Are there other patents affecting Stelara's market exclusivity?
Yes, in addition to the main patents, there are other patents covering various aspects of Stelara, including its formulation, method of use, and manufacturing [3]. These secondary patents could extend market exclusivity in both the US and EU beyond the expiration of the primary patent [3]. The precise expiration dates for these secondary patents vary and are crucial for determining the full duration of Stelara's protection [3]. DrugPatentWatch.com provides detailed information on these patent landscapes [3].
What does patent expiration mean for Stelara?
Once primary patents expire, it typically opens the door for generic manufacturers to seek approval and launch their own versions of the drug [4]. This can lead to increased competition and potentially lower drug prices [4]. However, the presence of secondary patents can complicate and delay the entry of generics [3][4].
When might biosimilars become available for Stelara?
The availability of biosimilars for Stelara is subject to the expiration of relevant patents and regulatory approvals in different regions [4]. The timeline for biosimilar entry can be complex due to patent challenges and litigation [3][4]. Information on biosimilar timelines for specific biologics like Stelara is often tracked by organizations specializing in pharmaceutical patent data [3].
Who are Stelara's main competitors?
Stelara is used to treat conditions such as plaque psoriasis, psoriatic arthritis, and Crohn's disease [5]. Competitors in these therapeutic areas include other biologic medications, and the market is dynamic with ongoing development of new treatments [5]. The introduction of biosimilars would represent a new form of competition.